Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer. They have found that the use of predictive biomarkers along with two targeted treatments significantly delays the need for conventional chemotherapy in patients with early-stage, but high-risk, chronic lymphoid leukemia (CLL).
- Researchers find predictive tests and early treatment delay progression of blood cell cancerThu, 6 Nov 2008, 18:43:25 EST
- New biomarker may predict leukemia aggressivenessSun, 19 Apr 2009, 15:43:11 EDT
- Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancerFri, 10 Dec 2010, 14:34:43 EST
- Biomarkers help predict prostate cancer progressionMon, 19 Apr 2010, 14:40:12 EDT
- M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patientsFri, 9 Apr 2010, 16:48:34 EDT